# Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)

> **NCT02243228** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Autoimmune Pulmonary Alveolar Proteinosis

## Interventions

- **DRUG:** GM-CSF

## Key facts

- **NCT ID:** NCT02243228
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2014-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243228, "Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02243228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*